Paper Search Console

Home Search Page About Contact

Journal Title

Title of Journal: Drugs

Search In Journal Title:

Abbravation: Drugs

Search In Journal Abbravation:

Publisher

Springer International Publishing

Search In Publisher:

DOI

10.1007/s11634-013-0157-z

Search In DOI:

ISSN

1179-1950

Search In ISSN:
Search In Title Of Papers:

Cobimetinib First Global Approval

Authors: Karly P GarnockJones
Publish Date: 2015/10/09
Volume: 75, Issue: 15, Pages: 1823-1830
PDF Link

Abstract

Genentech a subsidiary of Roche and Exelixis are developing cobimetinib an orally available small molecule for the treatment of various cancers including malignant melanoma and breast cancer Cobimetinib inhibits the MEK mitogenactivated protein kinase component of the MAPK/ERK signalling pathway which is frequently overactivated in human tumours The product has been approved in Switzerland in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutationpositive melanoma and is under regulatory review for the same indication in several countries including the USA and the EU This article summarizes the milestones in the development of cobimetinib leading to this first approval for unresectable or metastatic BRAF V600 mutationpositive melanoma melanomaThe preparation of this review was not supported by any external funding During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy K P GarnockJones is a salaried employee of Adis Springer SBM

Keywords:

References

.
Search In Abstract Of Papers:
Other Papers In This Journal:
  1. Ivabradine in Heart Failure
  2. Biosimilars for the Treatment of Chronic Inflammatory Diseases: A Systematic Review of Published Evidence
  3. Minimize the risk of chronic pain after cardiac surgery by treating acute postoperative pain
  4. Differentiating Factors Between Erythropoiesis-Stimulating Agents: An Update to Selection for Anaemia of Chronic Kidney Disease
  5. Pramipexole Extended-Release: A Review of Its Use in Patients with Parkinson’s Disease
  6. Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects
  7. Aspirin Inhibits Fractalkine Expression in Atherosclerotic Plaques and Reduces Atherosclerosis in ApoE Gene Knockout Mice
  8. Liposomal Amiodarone Augments Anti-arrhythmic Effects and Reduces Hemodynamic Adverse Effects in an Ischemia/Reperfusion Rat Model
  9. Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
  10. Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial
  11. Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction
  12. Cell cycle arrest through inhibition of tubulin polymerization by withaphysalin F, a bioactive compound isolated from Acnistus arborescens
  13. Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia
  14. Cost of Biologics in the Treatment of Juvenile Idiopathic Arthritis: A Factor not to be Overlooked
  15. Tocilizumab: A Review of Its Use in the Treatment of Juvenile Idiopathic Arthritis
  16. Efficacy and Safety of Tacrolimus Versus Cyclophosphamide for Primary Membranous Nephropathy: A Meta-Analysis
  17. Cell death induction in resting lymphocytes by pan-Cdk inhibitor, but not by Cdk4/6 selective inhibitor
  18. Examining the Quality of Medicines at Kenyan Healthcare Facilities: A Validation of an Alternative Post-Market Surveillance Model That Uses Standardized Patients
  19. Impact of Pharmacotherapy on Quality of Life in Patients with Parkinson ’ s Disease
  20. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer
  21. Inhibitory Effects of Azelnidipine Tablets on Morning Hypertension
  22. Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor
  23. Erythropoiesis Stimulating Agents in Heart Failure Patients with Anemia: A Meta-Analysis
  24. Cytokine Combination Therapy with Erythropoietin and Granulocyte Colony Stimulating Factor in a Porcine Model of Acute Myocardial Infarction
  25. Management of Chemotherapy-Induced Nausea and Vomiting
  26. Drug Treatment of Acute Ischemic Stroke
  27. Azelastine hydrochloride/fluticasone propionate combined in a single nasal spray: a guide to its use in allergic rhinitis
  28. Association between Acute Geriatric Syndromes and Medication-Related Hospital Admissions
  29. Insulin Degludec and Insulin Degludec/Insulin Aspart: A Review of Their Use in the Management of Diabetes Mellitus
  30. Adverse Drug Reactions in a Population of Hospitalized Very Elderly Patients
  31. Differences in maximum tolerated doses and approval doses of molecularly targeted oncology drug between Japan and Western countries
  32. Cardioprotective Properties of the Platelet P2Y 12 Receptor Inhibitor, Cangrelor: Protective in Diabetics and Reliant Upon the Presence of Blood
  33. Publication biases and phase II trials investigating anticancer targeted therapies
  34. Multi-drug inhibition of the HER pathway in metastatic colorectal cancer: Results of a phase I study of pertuzumab plus cetuximab in cetuximab-refractory patients
  35. Current Strategies to Reduce Gastrointestinal Bleeding Risk Associated with Antiplatelet Agents
  36. Potentially Inappropriate Medications in the Elderly in Korean Long-Term Care Facilities
  37. LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells
  38. Ranolazine Attenuates the Electrophysiological Effects of Myocardial Stretch in Langendorff-Perfused Rabbit Hearts
  39. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer
  40. The Impact of Age on Effects of Pre-hospital Initiation of High Bolus Dose of Tirofiban Before Primary Angioplasty for ST-Elevation Myocardial Infarction
  41. Steroid Use in Crohn’s Disease
  42. Sociodemographic Disparities in Administration of Antiepileptic Drugs to Adults with Epilepsy in Germany: A Retrospective, Database Study of Drug Prescriptions
  43. Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
  44. Risk versus Benefit of Non-Vitamin K Dependent Anticoagulants Compared to Warfarin for the Management of Atrial Fibrillation in the Elderly
  45. Acute Pancreatitis Following Brentuximab Vedotin Therapy for Refractory Hodgkin Lymphoma: A Case Report
  46. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus
  47. Volatile Substance Misuse
  48. A Systemic Combination Therapy with Granulocyte-Colony Stimulating Factor Plus Erythropoietin Aggravates the Healing Process of Balloon-Injured Rat Carotid Arteries
  49. Phosphodiesterase Inhibitors for Chronic Obstructive Pulmonary Disease: What Does the Future Hold?
  50. Postoperative Analgesia in Elderly Patients
  51. Deactylase inhibition in myeloproliferative neoplasms
  52. A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence
  53. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
  54. In vitro and in vivo antineoplastic and immunological effects of pterocarpanquinone LQB-118
  55. Warfarin Metabolites in Patients Following Cardiac Valve Implantation: A Contribution of Clinical and Genetic Factors
  56. A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
  57. Clinical Effectiveness of Tolvaptan in Patients with Acute Decompensated Heart Failure and Renal Failure: Design and Rationale of the AQUAMARINE Study
  58. The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
  59. Blackberry-induced hand-foot skin reaction to sunitinib
  60. A phase I study of S-1 with concurrent radiotherapy in elderly patients with locally advanced non-small cell lung cancer
  61. (+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9
  62. Comprehensive analysis of clinical development and regulatory submission promotion schemes for oncologic drugs as the Japanese national projects
  63. First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors
  64. Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics
  65. Shingles (Herpes Zoster) Vaccine (Zostavax ® ): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years
  66. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
  67. ZJU-6, a novel derivative of Erianin, shows potent anti-tubulin polymerisation and anti-angiogenic activities
  68. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression
  69. Degarelix: A Review of Its Use in Patients with Prostate Cancer
  70. A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
  71. Pretargeting of necrotic tumors with biotinylated hypericin using 123 I-labeled avidin: evaluation of a two-step strategy
  72. Phase 2 study of CT-322, a targeted biologic inhibitor of VEGFR-2 based on a domain of human fibronectin, in recurrent glioblastoma
  73. Purine analogs sensitize the multidrug resistant cell line (NCI-H460/R) to doxorubicin and stimulate the cell growth inhibitory effect of verapamil
  74. Adverse Effects of Immunosuppressant Drugs upon Airway Epithelial Cell and Mucociliary Clearance: Implications for Lung Transplant Recipients
  75. Worldwide Differences in Regulations of Clozapine Use
  76. Targeted Therapies for Advanced Oesophagogastric Cancer: Recent Progress and Future Directions
  77. Pembrolizumab: A Review in Advanced Melanoma
  78. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer
  79. Simeprevir: A Review of Its Use in Patients with Chronic Hepatitis C Virus Infection
  80. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma
  81. Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions
  82. Eltrombopag in severe aplastic anaemia: a guide to its use in the EU
  83. Study of Sustained Blood Pressure-Lowering Effect of Azelnidipine Guided by Self-Measured Morning and Evening Home Blood Pressure: Subgroup Analysis of the At-HOME Study
  84. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice
  85. Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine induced colonic aberrant crypt foci and bacterial enzyme activity in rats
  86. Lacosamide: A Review of Its Use as Adjunctive Therapy in the Management of Partial-Onset Seizures
  87. Post-Injection Delirium/Sedation Syndrome in Patients Treated with Olanzapine Pamoate: Mechanism, Incidence, and Management
  88. Anticholinergic Drug Use and Risk to Cognitive Performance in Older Adults with Questionable Cognitive Impairment: A Cross-Sectional Analysis
  89. Abstracts of the 5th International Conference of the Society for Heart and Vascular Metabolism
  90. A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)
  91. Personal experiences of electronic measurement of medication adherence in elderly stroke survivors
  92. Desloratadine: a guide to its use in allergic disorders
  93. Saliva Versus Plasma Bioequivalence of Azithromycin in Humans: Validation of Class I Drugs of the Salivary Excretion Classification System
  94. Naltrexone ER/Bupropion ER: A Review in Obesity Management
  95. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients with advanced solid tumors
  96. Polypharmacy and Potentially Inappropriate Medication in the Adult, Community-Dwelling Population in Switzerland
  97. The kinesin Eg5 inhibitor K858 induces apoptosis but also survivin-related chemoresistance in breast cancer cells
  98. Oral olanzapine: a guide to its use in adults with schizophrenia or bipolar I disorder
  99. Use of Statins and Risk of Dementia in Heart Failure: A Retrospective Cohort Study
  100. Phase 1 trial of Anvirzel™ in patients with refractory solid tumors
  101. Resveratrol Shows Vasoprotective Effect Reducing Oxidative Stress Without Affecting Metabolic Disturbances in Insulin-dependent Diabetes of Rabbits
  102. Nanofiltered human C1 inhibitor concentrate (Cinryze ® ): a guide to its use in hereditary angioedema in the EU
  103. Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
  104. Effects of Fetal Exposure to Maternal Chemotherapy
Search Result: